Comparative analysis of HIV type 1 genotypic resistance across antiretroviral trial treatment regimens

AIDS Research and Human Retroviruses

Volumn 16, Issue 14, 2000, Pages 1325-1336

  Gilbert, P B ^a   Hanna, G J ^b   De Gruttola, V ^a   Martinez Picado, J ^c   Kuritzkes, D R ^d   Johnson, V A ^e   Richman, D D ^f   D'Aquila, R T ^b  

^a CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; VIRUS MUTATION;

ANTI-HIV AGENTS; COMPUTATIONAL BIOLOGY; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0034692513     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/08892220050140874     Document Type: Article

References (53)

1. Antiretroviral drug resistance testing in adults with HIV infection
2. The implications of drug resistance for strategies of combination antiretroviral chemotherapy
3. Genetic correlates of in vivo viral resistance to indivanir, a human immunodeficiency type 1 protease inhibitor
4. Antiretroviral drug resistance in HIV-1
5. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation
6. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society - USA Panel
7. Performance evaluation of amino acid substitution matrices
8. Replicative fitness of protease inhibitor-resistant mutants of HIV-1
9. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase
10. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
11. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
12. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
13. Broad spectrum of in vivo human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215
14. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
15. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multidideoxynucleoside resistance
16. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy
17. Continued evolution of HIV-1 during combination therapy despite levels of HIV-1 < 500 copies/ml
18. Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types
19. Maximum likelihood estimation in semiparametric selection bias models with application to AIDS vaccine trials
20. Regression models for ordinal data (with discussion)
21. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection
22. Higher selection pressure from antiretroviral drugs in vivo results in increased evolutionary resistance in HIV-1 pol
23. Sequence clusters in human immunodeficiency virus type 1 reverse transcriptase are associated with subsequent virological response to antiretroviral therapy
24. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine
25. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1
26. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture
27. Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C → C1811)RT HIV-1 mutants
28. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
29. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes
30. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine
31. Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction
32. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)
33. Resistance to 2',3'-dideoxy-cytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase
34. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors
35. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxy- cytidine
36. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine
37. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility
38. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. Italy, The Netherlands, Canada and Australia Study
39. Comparison of competing risks failure time methods and time-independent methods for assessing strain variations in vaccine protection
40. The analysis of failure time in the presence of competing risks
41. Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficieney type 1 strain in the presence and absence of additional reverse transcriptase inhibitors
42. Resisting resistance: Maximizing the durability of antiretroviral therapy
43. Evolution of protein molecules
44. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences
45. Estimating evolutionary distances between DNA sequences
46. A structured model of HIV populations predicts differences in the frequency of antiretroviral-resistant mutations seen between untreated patients
47. Applications of semiparametric biased sampling models to AIDS vaccine and treatment trials